Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma - Related Studies - ClinicalTrials.gov

Skip to Main Content

ClinicalTrials.gov

Home Search Study Topics Glossary


	Full Text View


	Tabular View


	No Study Results Posted


	Related Studies

Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma

This study has been suspended.

Study NCT00201695 Information provided by Ohio State University Comprehensive Cancer Center

First Received: September 12, 2005 Last Updated: April 27, 2006 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Multiple Myeloma

Additional conditions recognized in this trial

Neoplasms, Plasma Cell

More general conditions related to this trial

Blood Protein Disorders
Cardiovascular Diseases
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Immune System Diseases
Immunoproliferative Disorders
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Paraproteinemias
Vascular Diseases

Interventions listed in this trial

Vincristine
Dexamethasone (DVd)
Arsenic Trioxide (Trisenox)

Additional drug interventions recognized in this trial

Arsenic trioxide
Dexamethasone
Dexamethasone acetate
Doxorubicin

Sponsors listed in this trial

Ohio State University Comprehensive Cancer Center

Back to top of Main Content